

ARMAN LIE

Partner, Fangda Partners

+852 3749 1160

arman.lie@fangdalaw.com



PRACTICE AREAS

ARMAN LIE IS A PARTNER IN THE CAPITAL MARKET GROUP AT FANGDA'S HONG KONG OFFICE.

HE SPECIALIZES IN CAPITAL MARKETS, M&A, PUBLIC AND PRIVATE PLACEMENTS AND OTHER FINANCING TRANSACTIONS, AND REPRESENTS LEADING CORPORATE AND FINANCIAL INSTITUTIONS, PRIVATE EQUITY FUNDS AND LISTED COMPANIES.

REPRESENTATIVE MATTERS AND CASES

Corporate Finance

- Represented Jinxin Fertility Group Limited (HKEx stock code: 1951) in its over US \$400 million global offering and initial public offering on the Main Board of the HKEx
- Represented Morgan Stanley and Huatai Financial as placing agents in the proposed H-Share private placement of WuXi AppTec Co., Ltd. (HKEx stock code: 2359) worth over HK \$7 billion
- Represented WuXi Biologics (Cayman) Inc. (HKEx stock code: 2269) and its controlling shareholders in successive primary and secondary placing transactions since WuXi's listing on the Main Board of the HKEx, with an aggregate transaction value of over US \$5 billion
- Represented Morgan Stanley, Huatai Financial and Goldman Sachs, as sponsors and global coordinators, in the US \$1 billion global H-Share offering of WuXi AppTec Co., Ltd. (HKEx stock code: 2359) on the Main Board of the HKEx
- Represented Bank of America, Morgan Stanley and China Merchants Securities as sponsors in the US \$510 million global offering and initial public offering of WuXi Biologics (Cayman) Inc. (HKEx stock code: 2269) on the Main Board of the HKEx
- Represented Citigroup and CCB International as joint sponsors and joint global coordinators in connection with the US \$113 million global offering and initial

public offering of Zhaoqing Kepei Education Group Limited (HKEx stock code: 1890) on the Main Board of the HKEx

- Represented Jinxin Healthcare Investment Management Group, a Sichuan-based international healthcare group, in its series A round of equity financing of USD \$140 million from Capital Group and GL Capital as pre-IPO investors
- Advised Fujifilm Corporation, as cornerstone investor, in the initial public offering and listing of China Resources Pharmaceutical Group Limited (HKEx stock code: 3320) on the Main Board of the HKEx
- Advised a PRC-based real estate property developer in a syndicated loan of USD \$175 million led by China CITIC Bank for group restructuring and settlement of outstanding exchangeable bonds
- Advised Harrow International and its affiliates in a term loan facility of HKD \$600 million from the Bank of East Asia and Heng Sang Bank for construction of the Harrow schools in Hong Kong

OTHER INFORMATION

Education

- The University of Hong Kong, PCLL
- The University of Hong Kong, LL.B.

Professional Qualification

Hong Kong

Languages

English, Mandarin Chinese and Cantonese